ICCC Quote, Financials, Valuation and Earnings

Becton, Dickinson & Co. has a net margin of -2.54% compared to ImmuCell Corp.'s net margin of 8.37%. ImmuCell Corp.'s return on equity of 8.15% beat Becton, Dickinson & Co.'s return on equity of 6.6%.

ImmuCell Corp. has a consensus price target of --, signalling upside risk potential of 128.76%. On the other hand Becton, Dickinson & Co. has an analysts' consensus of $204.83 which suggests that it could grow by 4.33%. Given that ImmuCell Corp. has higher upside potential than Becton, Dickinson & Co., analysts believe ImmuCell Corp. is more attractive than Becton, Dickinson & Co..

ImmuCell Corp. has a beta of 0.200, which suggesting that the stock is 79.986% less volatile than S&P 500. In comparison Becton, Dickinson & Co. has a beta of 0.252, suggesting its less volatile than the S&P 500 by 74.828%.

ImmuCell Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Becton, Dickinson & Co. offers a yield of 2.12% to investors and pays a quarterly dividend of $1.05 per share. ImmuCell Corp. pays -- of its earnings as a dividend. Becton, Dickinson & Co. pays out 71.53% of its earnings as a dividend. Becton, Dickinson & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

ImmuCell Corp. quarterly revenues are $5.5M, which are smaller than Becton, Dickinson & Co. quarterly revenues of $5.9B. ImmuCell Corp.'s net income of -$139.7K is lower than Becton, Dickinson & Co.'s net income of $493M. Notably, ImmuCell Corp.'s price-to-earnings ratio is 23.64x while Becton, Dickinson & Co.'s PE ratio is 33.68x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ImmuCell Corp. is 1.98x versus 2.59x for Becton, Dickinson & Co.. Usually stocks with elevated PS ratios are considered overvalued.

IDEXX Laboratories, Inc. has a net margin of -2.54% compared to ImmuCell Corp.'s net margin of 24.85%. ImmuCell Corp.'s return on equity of 8.15% beat IDEXX Laboratories, Inc.'s return on equity of 66.88%.

ImmuCell Corp. has a consensus price target of --, signalling upside risk potential of 128.76%. On the other hand IDEXX Laboratories, Inc. has an analysts' consensus of $766.00 which suggests that it could grow by 11.26%. Given that ImmuCell Corp. has higher upside potential than IDEXX Laboratories, Inc., analysts believe ImmuCell Corp. is more attractive than IDEXX Laboratories, Inc..

ImmuCell Corp. has a beta of 0.200, which suggesting that the stock is 79.986% less volatile than S&P 500. In comparison IDEXX Laboratories, Inc. has a beta of 1.668, suggesting its more volatile than the S&P 500 by 66.77%.

ImmuCell Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IDEXX Laboratories, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ImmuCell Corp. pays -- of its earnings as a dividend. IDEXX Laboratories, Inc. pays out -- of its earnings as a dividend.

ImmuCell Corp. quarterly revenues are $5.5M, which are smaller than IDEXX Laboratories, Inc. quarterly revenues of $1.1B. ImmuCell Corp.'s net income of -$139.7K is lower than IDEXX Laboratories, Inc.'s net income of $274.6M. Notably, ImmuCell Corp.'s price-to-earnings ratio is 23.64x while IDEXX Laboratories, Inc.'s PE ratio is 54.58x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ImmuCell Corp. is 1.98x versus 13.47x for IDEXX Laboratories, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals, Inc. has a net margin of -2.54% compared to ImmuCell Corp.'s net margin of -255.85%. ImmuCell Corp.'s return on equity of 8.15% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.

ImmuCell Corp. has a consensus price target of --, signalling upside risk potential of 128.76%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -82.47%. Given that ImmuCell Corp. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe ImmuCell Corp. is more attractive than NovaBay Pharmaceuticals, Inc..

ImmuCell Corp. has a beta of 0.200, which suggesting that the stock is 79.986% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.

ImmuCell Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. ImmuCell Corp. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

ImmuCell Corp. quarterly revenues are $5.5M, which are larger than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. ImmuCell Corp.'s net income of -$139.7K is higher than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, ImmuCell Corp.'s price-to-earnings ratio is 23.64x while NovaBay Pharmaceuticals, Inc.'s PE ratio is 8.15x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ImmuCell Corp. is 1.98x versus 9.42x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Precipio, Inc. has a net margin of -2.54% compared to ImmuCell Corp.'s net margin of -1.17%. ImmuCell Corp.'s return on equity of 8.15% beat Precipio, Inc.'s return on equity of -10.15%.

ImmuCell Corp. has a consensus price target of --, signalling upside risk potential of 128.76%. On the other hand Precipio, Inc. has an analysts' consensus of -- which suggests that it could fall by -20.03%. Given that ImmuCell Corp. has higher upside potential than Precipio, Inc., analysts believe ImmuCell Corp. is more attractive than Precipio, Inc..

ImmuCell Corp. has a beta of 0.200, which suggesting that the stock is 79.986% less volatile than S&P 500. In comparison Precipio, Inc. has a beta of 1.085, suggesting its more volatile than the S&P 500 by 8.543%.

ImmuCell Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Precipio, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ImmuCell Corp. pays -- of its earnings as a dividend. Precipio, Inc. pays out -- of its earnings as a dividend.

ImmuCell Corp. quarterly revenues are $5.5M, which are smaller than Precipio, Inc. quarterly revenues of $6.8M. ImmuCell Corp.'s net income of -$139.7K is lower than Precipio, Inc.'s net income of -$79K. Notably, ImmuCell Corp.'s price-to-earnings ratio is 23.64x while Precipio, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ImmuCell Corp. is 1.98x versus 1.62x for Precipio, Inc.. Usually stocks with elevated PS ratios are considered overvalued.